Microfluidics technology for physiologically relevant assays

Jeff Jensen, CEO of Fluxion Biosciences describes how microfluidics technology fuels drug discovery through physiologically relevant cell-based models

Related Keywords

United States , American , Acta Pharmaceutica Sinica , Jeff Jensen , Stem Cell Research Therapy , Drug Administration , Editorial Article , Fluxion Biosciences , Modernization Act , Physiology Cell , Reviews Drug Discovery , Analytical Chemistry , Cell Research , Catarina Rap , Microfluidics Technology Provides Physiologically Relevant Cell Based Models For High Throughput Drug Discovery Selectscience Cart Therapy , Microfluidic Technology , Cellular Interaction ,